Table 1.
Clinical characteristics of PCaP research subjects with available DNA
| African American
|
European American
|
|||
|---|---|---|---|---|
| NC | LA | NC | LA | |
| No. of subjects | 458 | 602 | 493 | 594 |
| Age at diagnosis | ||||
| Median | 60 | 63 | 64 | 65 |
| Range | 41–79 | 43–79 | 41–79 | 42–79 |
| Median PSA, ng/ml | 6 | 6 | 5 | 5 |
| PSA levels, N(%) | ||||
| <4 | 40 (8.7) | 67 (11.1) | 81 (16.4) | 92 (15.5) |
| 4–10 | 286 (62.4) | 327 (54.3) | 329 (66.7) | 373 (62.8) |
| 10–20 | 76 (16.6) | 94 (15.6) | 62 (12.6) | 61 (10.3) |
| >20 | 52 (11.3) | 62 (10.3) | 20 (4.1) | 35 (5.9) |
| Unknown | 4 (0.9) | 52 (8.6) | 1 (0.2) | 33 (5.6) |
| Gleason Score, N (%) | ||||
| ≤6 | 242 (52.8) | 344 (57.1) | 314 (63.7) | 360 (60.6) |
| 7 | 159 (34.7) | 174 (28.9) | 128 (26.0) | 162 (27.3) |
| 8–10 | 56 (12.2) | 82 (13.6) | 50 (10.1) | 68 (11.4) |
| Unknown | 1 (0.2) | 2 (0.3) | 1 (0.2) | 4 (0.7) |
| Pathologic stage*, N (%) | ||||
| T1 | 276 (60.3) | 294 (48.8) | 284 (57.6) | 309 (52.0) |
| T2 | 169 (36.9) | 272 (45.2) | 203 (41.2) | 251 (42.3) |
| T3–T4 | 11 (2.4) | 8 (1.3) | 4 (0.8) | 14 (2.4) |
| Unknown | 2 (0.4) | 28 (4.6) | 2 (0.4) | 20 (3.4) |
| Aggressiveness, n (%) | ||||
| Low | 209 (45.6) | 260 (43.2) | 284 (57.6) | 301 (50.7) |
| Intermediate | 157 (34.3) | 174 (28.9) | 142 (28.8) | 170 (28.6) |
| High | 92 (20.1) | 120 (19.9) | 66 (13.4) | 92 (15.5) |
| Unknown | 0 (0) | 48 (8.0) | 1 (0.2) | 31 (5.2) |
*
For the 81 subjects (3.9%) missing pathological stage, clinical stage was used.